全球中期老年性黃斑部病變市場：各地區分析與預測（2025-2035）

中期老年性黃斑部病變是一種進行性視網膜疾病，常見於 50 歲或以上的人群，被認為是視力障礙的主要原因之一，尤其是對老年人而言。

中期老年性黃斑部病變盛行率的上升和全球人口老化是該市場的主要成長要素。除年齡外，遺傳因素、吸菸和長時間暴露於紫外線也被認為是增加患病風險的因素。隨著老年人口的持續成長，對有效治療方法和診斷工具的需求預計將進一步增加，市場規模有望擴大。

老年性黃斑部病變市場的一個關鍵發展是抗VEGF療法的應用日益廣泛。這些治療方法已證明在減緩濕性老齡化性黃斑部病變進展方面非常有效，其在中期老年性黃斑部病變的潛在應用也研究中。未來，預計抗VEGF療法將被用作預防疾病發展至重症階段的手段。細胞療法、基因療法以及其他創新候選療法的出現也促進了市場的擴張。

除了藥物治療外，光同調斷層掃瞄（OCT）和眼底螢光（FAF）等先進影像技術的使用，徹底改變過渡時期AMD 的診斷和後續觀察。這些技術能夠詳細觀察視網膜層級構造，能夠在視力喪失進展之前及早發現疾病徵兆。此外，人工智慧（AI）融入 OCT 和 FAF 影像分析，提高了診斷準確性，使其能夠更有效地預測病情進展並制定個人化治療方案。

此外，為解決中期老年性黃斑部病變所致的功能障礙，對視覺復健服務的需求日益成長。這些服務致力於最大限度地提高剩餘視力並改善生活品質，這是推動市場成長的因素之一。隨著研發的進步，中期老年性黃斑部病變市場未來有望實現更有針對性的治療方法和更先進的診斷工具的實用化，推動市場持續擴張。

本報告調查了全球中期老年性黃斑部病變市場，並總結了主要趨勢、影響市場的因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

執行摘要

第1章 全球中期老年性黃斑部病變市場：產業展望

• 市場趨勢
• 法律規範
• 中期老年性黃斑部病變的流行病學
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機會

第2章 全球中期老年性黃斑部病變市場：依地區

• 北美洲
• 歐洲
• 亞太地區
  • 主要調查結果
  • 市場動態
  • 市場規模及預測

第3章 全球中期老年性黃斑部病變市場：競爭格局與公司概況

• 主要發展和策略
  • M&A
  • 協同努力
  • 業務擴展和資金籌措
  • 產品發布和核准
  • 其他活動
• 公司簡介
  • Novartis AG
  • Allegro Ophthalmics, LLC.
  • Apellis Pharmaceuticals

第4章 調查方法

Global Intermediate Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035

Intermediate age-related macular degeneration is a progressive retinal condition that typically affects individuals aged 50 and older. It is a major cause of vision impairment, particularly in the aging population. The growing prevalence of intermediate age-related macular degeneration, coupled with an aging global population, is a key driver of the market. In addition to aging, risk factors such as genetics, smoking, and prolonged exposure to sunlight contribute to the disease's increasing incidence. As the population continues to age, the demand for effective treatments and diagnostic tools for intermediate age-related macular degeneration is expected to grow, driving market expansion.

A critical development in the age-related macular degeneration market is the increasing use of anti-VEGF (vascular endothelial growth factor) therapies. These treatments have shown significant efficacy in slowing the progression of wet age-related macular degeneration, and while their use in intermediate age-related macular degeneration is still under investigation, they are expected to play a role in preventing the advancement to more severe stages. The growing availability of novel therapies, including cell and gene therapies and other innovative drug candidates, is also contributing to the market's expansion.

In addition to pharmacological treatments, the use of advanced imaging technologies such as optical coherence tomography (OCT) and fundus autofluorescence (FAF) is revolutionizing the diagnosis and monitoring of intermediate age-related macular degeneration. These imaging tools allow for a detailed examination of the retinal layers, enabling early detection of disease progression before significant vision loss occurs. The integration of artificial intelligence (AI) in the analysis of OCT and FAF images further enhances diagnostic precision, offering clinicians tools to predict disease progression and tailor treatment plans more effectively.

Moreover, the demand for vision rehabilitation services is rising as a means to help patients cope with the functional limitations imposed by intermediate age-related macular degeneration. These therapies, which focus on maximizing remaining vision and improving quality of life, are contributing to the market's growth. As research advances, the future of the intermediate age-related macular degeneration market holds promise for more targeted therapies and improved diagnostic tools, driving overall market expansion.

Despite the positive growth trajectory, several challenges continue to impact the global intermediate age-related macular degeneration market. One of the primary challenges is the high cost of advanced treatments, particularly anti-VEGF (vascular endothelial growth factor) injections, represents a significant financial challenge for both patients and healthcare systems. Anti-VEGF therapies are used to treat a variety of retinal diseases, such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. These treatments aim to inhibit the growth of abnormal blood vessels in the retina, which can lead to vision loss if left untreated.

Moreover, the side effects of current therapies may pose a major barrier to market growth, one of the most common risks associated with anti-VEGF injections is eye infections, such as endophthalmitis. This condition, although rare, can lead to severe complications, including vision loss. The risk of infection is especially concerning since the injections involve introducing medication directly into the eye, making it an invasive procedure.

As the global intermediate age-related macular degeneration market continues to grow, key trends such as advancements in early diagnostic technologies, the development of novel therapeutic approaches, and the increasing use of personalized treatments are expected to drive market expansion. The rising aging population and the growing awareness of the condition's impact on vision health are contributing to the higher demand for effective age-related macular degeneration treatments. Innovations in drug delivery systems, such as sustained-release intravitreal implants, and the increasing adoption of minimally invasive therapies are expected to enhance treatment outcomes and patient satisfaction. Additionally, research into genetic and environmental factors is paving the way for more tailored therapeutic options.

In conclusion, the global intermediate age-related macular degeneration market is set for robust growth, fueled by technological innovations in diagnostics and treatment, a rising aging demographic, and a growing focus on improving vision health. As healthcare providers and researchers continue to develop more effective and personalized therapies, there will be substantial opportunities for both new and established market players to address the unmet needs of age-related macular degeneration patients, ultimately improving patient outcomes and quality of life.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Intermediate Age-Related Macular Degeneration Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology of Intermediate Age-Related Macular Degeneration
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Intermediate Age-Related Macular Degeneration Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Intermediate Age-Related Macular Degeneration Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Intermediate Age-Related Macular Degeneration Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
      • 2.2.3.1.5 Spain
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Intermediate Age-Related Macular Degeneration Market, by Country
      • 2.3.3.1.1 Japan

3. Global Intermediate Age-Related Macular Degeneration Market: Competitive Landscape and Company Profiles

• 3.1 Key Developments and Strategies
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 Novartis AG
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Target Customers/End-Users
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 Allegro Ophthalmics, LLC.
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Target Customers/End-Users
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 Apellis Pharmaceuticals
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Target Customers/End-Users
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Intermediate Age-Related Macular Degeneration Market (by Region), $Million, 2024 and 2035
• Figure: Epidemiology of Intermediate Age-Related Macular Degeneration
• Figure: Global Intermediate Age-Related Macular Degeneration Market Coverage
• Figure: Global Intermediate Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Intermediate Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Intermediate Age-Related Macular Degeneration Market, Clinical Trial Analysis
• Table: Global Intermediate Age-Related Macular Degeneration Market Dynamics, Impact Analysis
• Table: Global Intermediate Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035